Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Related: Shannon Miller on Her Ovarian Cancer Diagnosis. The Early Ovarian Cancer Sign Most People Miss. According to experts ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...